Testimony of Brett P. Giroir and Kimberly Brandt at Hearing Titled Tackling Opioid and Substance Use Disorders in Medicare, Medicaid, and Human Services Programs. April 19, 2018.
Giroir, Brett P. Brandt, Kimberly.
United States Department of Health and Human Services.
Published: August 2018
U.S. Senate Committee On Finance
219 Dirksen Senate Office Building
Washington, DC 20510-6200
Tel: 202-224-4515 (majority) 202-224-5315 (minority)
This testimony provided to the U.S. Senate Committee on Finance, discusses activities undertaken by the U.S. Department of Health and Human Services (HHS) to address opioid and substance use disorders in Medicare, Medicaid, and human services programs. It explains that in April 2017, HHS outlined its five-point Opioid Strategy, which provides the overarching framework to leverage the expertise and resources of HHS agencies in a strategic and coordinated manner. The comprehensive, evidence-based Opioid Strategy aims to: improve access to prevention, treatment, and recovery support services to prevent the health, social, and economic consequences associated with opioid addiction and to enable individuals to achieve long-term recovery; target the availability and distribution of overdose-reversing medications to ensure the broad provision of these drugs; strengthen public health data reporting and collection to improve the timeliness and specificity of data and to inform a real-time public health response as the epidemic evolves; support cutting-edge research that advances understanding of pain and addiction, leads to the development of new treatments, and identifies effective public health interventions; and advance the practice of pain management to enable access to high-quality, evidence- based pain care that reduces the burden of pain and the inappropriate use of opioids. The role of the Centers for Medicare & Medicaid Services in addressing the opioid crisis is reviewed, as well as the role of the Administration for Children and Families and activities taken by the Office of the Assistant Secretary for Health (OASH), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Diseases Control and Prevention (CDC), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA).
opioid addiction; federal programs; substance abuse treatment; prevention programs; health services; policy formation; medicaid